Nymox Pharmaceutical Statistics
Total Valuation
NYMXF has a market cap or net worth of $912,650. The enterprise value is $14.46 million.
| Market Cap | 912,650 |
| Enterprise Value | 14.46M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
NYMXF has 91.27 million shares outstanding.
| Shares Outstanding | 91.27M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 42.05% |
| Owned by Institutions (%) | 0.14% |
| Float | 53.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.19
| Current Ratio | 0.19 |
| Quick Ratio | 0.15 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -86.18 |
Financial Efficiency
Return on equity (ROE) is -1,589.50%.
| Return on Equity (ROE) | -1,589.50% |
| Return on Assets (ROA) | -117.20% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.28% in the last 52 weeks. The beta is 0.22, so NYMXF's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | -81.28% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.47 |
| Relative Strength Index (RSI) | 24.20 |
| Average Volume (20 Days) | 10,294 |
Short Selling Information
The latest short interest is 2.03 million, so 2.23% of the outstanding shares have been sold short.
| Short Interest | 2.03M |
| Short Previous Month | 2.08M |
| Short % of Shares Out | 2.23% |
| Short % of Float | 3.83% |
| Short Ratio (days to cover) | 59.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.96M |
| Pretax Income | -2.88M |
| Net Income | -2.88M |
| EBITDA | -2.60M |
| EBIT | -2.84M |
| Earnings Per Share (EPS) | -$0.04 |
Balance Sheet
The company has $351,000 in cash and $114,000 in debt, giving a net cash position of $237,000 or $0.00 per share.
| Cash & Cash Equivalents | 351,000 |
| Total Debt | 114,000 |
| Net Cash | 237,000 |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | -1.80M |
| Book Value Per Share | -0.02 |
| Working Capital | -1.91M |
Cash Flow
In the last 12 months, operating cash flow was -$1.99 million and capital expenditures -$3,000, giving a free cash flow of -$1.99 million.
| Operating Cash Flow | -1.99M |
| Capital Expenditures | -3,000 |
| Free Cash Flow | -1.99M |
| FCF Per Share | -$0.02 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NYMXF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.22% |
| Shareholder Yield | -5.22% |
| Earnings Yield | -19.58% |
| FCF Yield | -13.54% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |